Tactile Medical projects $360M-$366M 2026 revenue as airway clearance ordering normalizes in Q4 (NASDAQ:TCMD)
TCMD Q2 2026 earnings call recap: raised revenue guidance to $360â$366M, lymphedema strength, AffloVest inventory reset, Medicare prior auth impactâread...
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
TCMD Q2 2026 earnings call recap: raised revenue guidance to $360â$366M, lymphedema strength, AffloVest inventory reset, Medicare prior auth impactâread...
Tactile Medical projects $360M-$366M 2026 revenue as airway clearance ordering normalizes in Q4 (NASDAQ:TCMD) | Seeking Alpha
Earnings Call Insights: Tactile Systems Technology (TCMD) Q2 2026
Management view
"We delivered another strong quarter of execution in Q2, highlighted by continued strength in our lymphedema business and meaningful profitability expansion." (CEO, President & Director Sheri Dodd)
"Based on
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
What are the main drivers of Tactile Systems Technology's updated 2026 revenue guidance?
Lymphedema business strength and launch of new distribution agreement with ElastiMed are boosting revenue, while airway clearance segment faces temporary inventory disruptions.
How are Medicare prior authorization and inventory management affecting TCMD's lymphedema and airway clearance businesses?
Medicare prior authorization has caused near-term moderation in lymphedema order volumes, and inventory management dynamics among DME partners have led to a temporary decline in airway clearance revenue, expected to normalize later in the year.
What is the impact of AffloVest inventory dynamics and product launches on TCMD's financial outlook?
AffloVest ordering dropped due to partners managing inventory post-next-gen launch; management expects this to continue through Q3 but normalize in Q4, with the potential for resumed growth once inventory levels rebalance.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.
Sidus Fortis VPX Commercial Launch in 2027 Backed by $158.5M Funding
Sidus Space announces the commercial availability of its Fortis VPX edge computing module by early 2027, supported by $158.5M raised in Q2 2025. Learn about its technology advantages, market outlook, and financial health.
TOMI Reaffirms 2026 Revenue Guidance of at Least $12M, Sets $10M Funding Goal for Carbonium Core Merger
TOMI Environmental Solutions reaffirms its 2026 revenue guidance of at least $12 million and advances its merger with Carbonium Core, targeting $10 million in funding. This article analyzes the strategic implications, industry context, and potential risks.
